← All causality assessments
Causality assessment · Coding artifact: the indication reported back as the "reaction"

Estradiol/Norethindrone Acetate and Breast Cancer: is the FAERS signal real?

n=281 co-reports · PRR 32.7 · ROR 38.2
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Coding artifact: the indication reported back as the "reaction"

Estradiol/Norethindrone Acetate ↔ Breast Cancer

n=281 co-reports · PRR 32.7 · ROR 38.2

Carbidopa, levodopa (Rytary) is a controlled-release dopamine replacement for Parkinson disease. The co-reporting of Parkinson as a reaction is a coding artifact: patients on Rytary for Parkinson have the indication recorded as the AE. 1,291 co-reports (PRR 11.8) reflect the treated population.

Coding artifact: Parkinson is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Estradiol/Norethindrone captured breast cancer as a tracked adverse event in a usable structure. Parkinson is the indication; trials do not track it as an AE.